Combination therapy for treating disease

A method for treating cancer in a patient, comprising:

• (1) surgically removing the cancer, and
• (2) administering a composition comprising an unlabeled xenotypic monoclonal antibody at weeks 1, 3, 5, 7 and 9, followed by concurrently administering a chemotherapeutic drug and the composition, said xenotypic monoclonal antibody in the composition is administered in a dose less than or equal to 2 mg at week 12.

A method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen comprising administering to the patient a chemotherapeutic drug and a composition comprising an unlabeled monoclonal antibody or a fragment thereof that specifically binds to a first epitope on the antigen and allowing the monoclonal antibody or fragment thereof to form a monoclonal antibody or fragment thereof / antigen pair, wherein a host immune response is elicited against a second epitope on the antigen, wherein antigen is selected from the group consisting of MUC-1, CA 125, prostate specific antigen, CA 19.9 or TAG-72, wherein said antigen does not elicit an effective host immune response, wherein the chemotherapeutic drug is administered within a week of administering the monoclonal antibody and wherein the monoclonal antibody is selected from the group consisting of:

• Alt-1 which is producible by a hybridoma having ATCC deposit number PTA-975, Alt-2 which is producible by a hybridoma having ATCC deposit number PTA-1883, Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2692, Alt-5 which is producible by a hybridoma having ATCC deposit number PTA-2690, and Alt-6 which is producible by a hybridoma having ATCC deposit number RB 12526.

A method for treating cancer, comprising administering a chemotherapeutic drug, an antigen, and a monoclonal antibody or a fragment thereof that binds the antigen, wherein the chemotherapeutic drug is administered within a week of administering the monoclonal antibody and wherein the monoclonal antibody is selected from the group consisting of:

• Alt-1 which is producible by a hybridoma having ATCC deposit number PTA-975, Alt-2 which is producible by a hybridoma having ATCC deposit number PTA-1883, Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2692, Alt-5 which is producible by a hybridoma having ATCC deposit number PTA-2690, and Alt-6 which is producible by a hybridoma having ATCC deposit number HB 12526.